At 4:00 PM ET on Tuesday, June 4, 2013, Mr. Peter Arduini, President and Chief Executive Officer of Integra, will present at the Jefferies 2013 Global Healthcare Conference in New York, NY.

Integra LifeSciences has set its FY13 guidance at $2.40-2.70 EPS. On average, analysts predict that Integra LifeSciences will post $2.51 earnings per share for the current fiscal year.

Is the current inventory situation at Integra LifeSciences Holdings (NAS: IART) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Integra LifeSciences Holdings doing by this quick checkup? At ...

Integra Lifesciences To Present At Jefferies Conference; Webcast At 4:00 PM ET. By RTT News, June 04, 2013, 03:00:00 PM EDT. Vote up.

Integra LifeSciences presently has an average rating of Hold and an average price target of $42.08. Integra LifeSciences Holdings Corporation (NASDAQ: IART) is an integrated medical device company. To view Zacks' full report, visit www.zacks.com.

Integra LifeSciences has a 52 week low of $30.87 and a 52 week high of $44.53. The stock's 50-day moving average is currently $38.10.

Let's check out hedge fund and insider activity in other stocks similar to Insulet Corporation (NASDAQ:PODD). These stocks are Hill-Rom Holdings, Inc. (NYSE:HRC), Endologix, Inc. (NASDAQ:ELGX), Integra Lifesciences Holdings Corp (NASDAQ:IART), ...

Integra LifeSciences Holdings Corporation (NASDAQ: IART) traded at $37.8407, up 2.5 pct during After Hours on 1,500 shares.

She is also the managing director of Prettybrook Partners, which she operates with her partner, Stuart Essig, former CEO of Integra Lifesciences (NASDAQ: IART), a former board member of Zimmer Holdings, Inc. (NYSE: ZMH), and a current board member of ...

As a result, we are lowering the ratings of a handful of our companies as well as removing one company from our Best Ideas List and adding another in its place due primarily to valuation.